{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:24:18Z","timestamp":1784298258619,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00104-022-01661-4","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:03:40Z","timestamp":1655478220000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hepatozellul\u00e4res Karzinom","Hepatocellular carcinoma"],"prefix":"10.1007","volume":"93","author":[{"given":"Felix","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost Philipp","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"Dobbermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Linecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"issue":"5","key":"1661_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/hep.32240","volume":"75","author":"SK Asrani","year":"2022","unstructured":"Asrani\u00a0SK et\u00a0al (2022) Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 75(5):1289\u20131299","journal-title":"Hepatology"},{"key":"1661_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11377-019-0352-3","volume":"14","author":"A Bernsmeier","year":"2019","unstructured":"Bernsmeier\u00a0A, Braun\u00a0F (2019) Lebertransplantation bei prim\u00e4ren Lebertumoren und Lebermetastasen. Gastroenterologe 14:269\u2013281","journal-title":"Gastroenterologe"},{"key":"1661_CR3","unstructured":"Bundes\u00e4rztekammer (2021) Richtlinie gem. \u00a7 16 Abs. 1 S. 1 Nrn. 2 und 5 TPG f\u00fcr die Wartelistenf\u00fchrung und Organvermittlung zur Lebertransplantation. http:\/\/www.bundesaerztekammer.de\/fileadmin\/user_upload\/downloads\/pdf-Ordner\/RL\/RiliOrgaWlOvLeberTx20211102.pdf. Zugegriffen:: 31.05.2022"},{"key":"1661_CR4","doi-asserted-by":"publisher","unstructured":"Cunha GM, Hosseini M, Furlan A, Fowler KJ (2022) Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation. AJR Am J Roentgenol 218(1):77\u201386. https:\/\/doi.org\/10.2214\/AJR.21.26436. Epub 2021 Aug 18. PMID: 34406054","DOI":"10.2214\/AJR.21.26436"},{"key":"1661_CR5","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB el-Khoueiry","year":"2017","unstructured":"el-Khoueiry\u00a0AB et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389:2492\u20132502","journal-title":"Lancet"},{"issue":"1","key":"1661_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J\u00a0Hepatol 69(1):182\u2013123","journal-title":"J Hepatol"},{"key":"1661_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/hep.28339","volume":"63","author":"J Ferrer-F\u00e0brega","year":"2016","unstructured":"Ferrer-F\u00e0brega\u00a0J et al (2016) Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 63:839\u2013849","journal-title":"Hepatology"},{"key":"1661_CR8","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn\u00a0RS et\u00a0al (2020) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J\u00a0Clin Oncol 38:2960\u20132970","journal-title":"J Clin Oncol"},{"key":"1661_CR9","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1007\/s00261-021-03165-x","volume":"46","author":"M Gerena","year":"2021","unstructured":"Gerena\u00a0M et al (2021) LI-RADS treatment response assessment of combination locoregional therapy for HCC. Abdom Radiol 46:3634\u20133647","journal-title":"Abdom Radiol"},{"issue":"6","key":"1661_CR10","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.3390\/jcm10061155","volume":"10","author":"JP Gundlach","year":"2021","unstructured":"Gundlach\u00a0JP et\u00a0al (2021) Indication of liver transplantation for hepatocellular carcinoma should be reconsidered in case of microvascular invasion and multilocular tumor occurrence. J\u00a0Clin Med 10(6):1155","journal-title":"J Clin Med"},{"issue":"1","key":"1661_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach\u00a0JK et\u00a0al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358\u2013378","journal-title":"Hepatology"},{"issue":"3","key":"1661_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00117-022-00972-1","volume":"62","author":"P Huppert","year":"2022","unstructured":"Huppert\u00a0P (2022) Transarterielle Chemoembolisation des hepatozellul\u00e4ren Karzinoms. Radiologe 62(3):225\u2013233","journal-title":"Radiologe"},{"issue":"S1","key":"1661_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hep.31424","volume":"73","author":"R Kloeckner","year":"2020","unstructured":"Kloeckner\u00a0R, Galle\u00a0PR, Bruix\u00a0J (2020) Local and regional therapies for hepatocellular carcinoma. Hepatology 73(S1):137\u2013149","journal-title":"Hepatology"},{"issue":"6","key":"1661_CR14","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3390\/ijms20061465","volume":"20","author":"I Lurje","year":"2019","unstructured":"Lurje\u00a0I et\u00a0al (2019) Treatment strategies for hepatocellular carcinoma \u2013 a\u00a0multidisciplinary approach. Int J Mol Sci 20(6):1465","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1661_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00270-021-02810-8","volume":"44","author":"MM Matsumoto","year":"2021","unstructured":"Matsumoto\u00a0MM et al (2021) Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-patient analysis. Cardiovasc Intervent Radiol 44(7):1070\u20131080","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11 Suppl 2","key":"1661_CR16","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1002\/lt.21330","volume":"13","author":"V Mazzaferro","year":"2007","unstructured":"Mazzaferro\u00a0V (2007) Results of liver transplantation: with or without Milan criteria? Liver Transpl 13(11 Suppl 2):S44\u2013S47","journal-title":"Liver Transpl"},{"issue":"S1","key":"1661_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2020","unstructured":"McGlynn\u00a0KA, Petrick\u00a0JL, El\u2010Serag\u00a0HB (2020) Epidemiology of Hepatocellular carcinoma. Hepatology 73(S1):4\u201313","journal-title":"Hepatology"},{"issue":"3","key":"1661_CR18","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3390\/jcm10030456","volume":"10","author":"AS Mehdorn","year":"2021","unstructured":"Mehdorn\u00a0AS et al (2021) Usability of Indocyanine green in robot-assisted hepatic surgery. J\u00a0Clin Med 10(3):456","journal-title":"J Clin Med"},{"issue":"5","key":"1661_CR19","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","volume":"161","author":"N Mehta","year":"2021","unstructured":"Mehta\u00a0N et al (2021) Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium. Gastroenterology 161(5):1502\u20131512","journal-title":"Gastroenterology"},{"issue":"Suppl 0","key":"1661_CR20","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","volume":"47","author":"S Mittal","year":"2013","unstructured":"Mittal\u00a0S, El-Serag\u00a0HA (2013) Epidemiology of hepatocellular carcinoma: consider the population. J\u00a0Clin Gastroenterol 47(Suppl 0):S2\u2013S6","journal-title":"J Clin Gastroenterol"},{"key":"1661_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2147\/JHC.S268288","volume":"8","author":"G Moura Cunha","year":"2021","unstructured":"Moura Cunha\u00a0G et al (2021) Up-to-date role of CT\/MRI LI-RADS in hepatocellular carcinoma. J\u00a0Hepatocell Carcinoma 8:513\u2013527","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"1661_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2016.10.038","volume":"66","author":"A Notarpaolo","year":"2017","unstructured":"Notarpaolo\u00a0A et al (2017) Validation of the AFP model as a\u00a0predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a\u00a0liver transplant for HCC. J\u00a0Hepatol 66(3):552\u2013559","journal-title":"J Hepatol"},{"issue":"2","key":"1661_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jhep.2013.04.006","volume":"59","author":"G Otto","year":"2013","unstructured":"Otto\u00a0G et\u00a0al (2013) How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J\u00a0Hepatol 59(2):279\u2013284","journal-title":"J Hepatol"},{"issue":"4","key":"1661_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","volume":"75","author":"R Pinyol","year":"2021","unstructured":"Pinyol\u00a0R et al (2021) Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J\u00a0Hepatol 75(4):865\u2013878","journal-title":"J Hepatol"},{"issue":"3","key":"1661_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2021","unstructured":"Reig\u00a0M et\u00a0al (2021) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J\u00a0Hepatol 76(3):681\u2013693","journal-title":"J Hepatol"},{"issue":"6","key":"1661_CR26","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/hep.28643","volume":"64","author":"G Sapisochin","year":"2016","unstructured":"Sapisochin\u00a0G et\u00a0al (2016) The extended toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology 64(6):2077\u20132088","journal-title":"Hepatology"},{"key":"1661_CR27","doi-asserted-by":"publisher","unstructured":"Tang A, Fowler KJ, Chernyak V, Chapman WC, Sirlin CB (2018). LI-RADS and transplantation for hepatocellular carcinoma. Abdom Radiol (NY) 43(1):193\u2013202. https:\/\/doi.org\/10.1007\/s00261-017-1210-8. PMID: 28612162","DOI":"10.1007\/s00261-017-1210-8"},{"issue":"2","key":"1661_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jhep.2019.11.017","volume":"72","author":"E Vibert","year":"2020","unstructured":"Vibert\u00a0E et\u00a0al (2020) Advances in resection and transplantation for hepatocellular carcinoma. J\u00a0Hepatol 72(2):262\u2013276","journal-title":"J Hepatol"},{"issue":"1","key":"1661_CR29","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1055\/a-1589-7585","volume":"60","author":"S Voesch","year":"2022","unstructured":"Voesch\u00a0S et al (2022) S3-Leitlinie: Diagnostik und Therapie des hepatozellul\u00e4ren Karzinoms \u2013 Langversion 2.0 \u2013 Juni 2021, AWMF-Registernummer: 032-0530L. Z\u00a0Gastroenterol 60(1):e131\u2013e185","journal-title":"Z Gastroenterol"},{"issue":"2","key":"1661_CR30","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1055\/a-1649-8643","volume":"60","author":"A Vogel","year":"2022","unstructured":"Vogel\u00a0A et al (2022) The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit\/risk assessment. Z\u00a0Gastroenterol 60(2):184\u2013191","journal-title":"Z Gastroenterol"},{"issue":"5","key":"1661_CR31","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/hep.31992","volume":"74","author":"TCL Wong","year":"2021","unstructured":"Wong\u00a0TCL et\u00a0al (2021) Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant. Hepatology 74(5):2580\u20132594. https:\/\/doi.org\/10.1002\/hep.31992","journal-title":"Hepatology"},{"issue":"11","key":"1661_CR32","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau\u00a0T et\u00a0al (2020) Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial. JAMA Oncol 6(11):e204564","journal-title":"JAMA Oncol"},{"key":"1661_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu\u00a0AX et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940\u2013952","journal-title":"Lancet Oncol"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-022-01661-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T08:05:33Z","timestamp":1656576333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-022-01661-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1661"],"URL":"https:\/\/doi.org\/10.1007\/s00104-022-01661-4","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"12 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Braun, J.P.\u00a0Sch\u00e4fer, H.\u00a0Dobbermann, T.\u00a0Becker und M.\u00a0Linecker geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}